Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment

Background: Even though PD-1/PD-L1 is an identified key “don't find me” signal to active adaptive immune system for cancer treatment, the overall response rate (ORR) for all cancer patients is still limited. Other effective therapeutic modalities to bridge the innate and adaptive immunity to im...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Rongjuan, Zhang, Chang, Cao, Yuting, Wang, Junchao, Jiao, Shasha, Zhang, Jiao, Wang, Min, Tang, Peipei, Ouyang, Zijun, Liang, Wenlu, Mao, Yu, Wang, An, Li, Gang, Zhang, Jinchao, Wang, Mingzhu, Wang, Shuang, Gui, Xun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800731/
https://www.ncbi.nlm.nih.gov/pubmed/36593962
http://dx.doi.org/10.7150/thno.79367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800731/
https://www.ncbi.nlm.nih.gov/pubmed/36593962
http://dx.doi.org/10.7150/thno.79367

Ejemplares similares